FDA Clears Biosense Webster Direct Contact Force Catheter Ablation Therapy

 

February 28, 2014
Biosense Webster Thermocool Smarttouch Catheter Atrial Fibrillation Ablation EP

Biosense Webster Inc.’s Thermocool Smarttouch Catheter enables direct and real-time measurement of contact force during catheter ablation procedures for patients suffering from drug-resistant paroxysmal atrial fibrillation (Afib), sustained monomorphic ischemic ventricular tachycardia and Type I atrial flutter.

The Thermocool Smarttouch Catheter provides direct, real-time quantitative feedback graphically displayed on the company’s Carto 3 System upon tissue contact. 

The U.S. Food and Drug Administration (FDA) approved Biosense Webster Inc.’s Thermocool Smarttouch Catheter in February 2014. 

For more information: www.biosensewebster.com